ELGN GI
Alternative Names: ELGN-GI; NTRA-2112Latest Information Update: 07 Aug 2023
At a glance
- Originator Nutrinia
- Developer Elgan Pharma
- Class Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Gastrointestinal disorders
Most Recent Events
- 09 Mar 2023 Phase-III clinical trials in Gastrointestinal disorders (In infants) in Austria (PO) (EudraCT2021-004890-29)
- 09 Mar 2023 Phase-III clinical trials in Gastrointestinal disorders (In infants) in Sweden (PO) (EudraCT2021-004890-29)
- 09 Mar 2023 Elgan Pharma initiates a phase II Basket study for Gastriintestinal disorder in Netherlands and France (PO) (before March 2023) (EudraCT2022-004195-42)